1672.HK Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 apr 2024 @ 07:17):

Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China and internationally...

Stats
Dagens volum	1.42M
Gjennomsnittsvolum	941 237
Markedsverdi	1.36B
EPS	HKD0 ( 2023-08-22 )
Neste inntjeningsdato	( HKD0 ) 2024-05-23
Last Dividend	HKD0 ( N/A )
Next Dividend	HKD0 ( N/A )
P/E	-8.67
ATR14	HKD0.00500 (0.38%)

Volum Korrelasjon

Lang: 0.04 (neutral)

Kort: -0.20 (neutral)

Signal:(49.624) Neutral

Ascletis Pharma Inc Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Ascletis Pharma Inc Korrelasjon - Valuta/Råvare

-0.16
( neutral )

-0.53
( weak negative )

0.00
( neutral )

0.13
( neutral )

Ascletis Pharma Inc Økonomi

Annual	2023
Omsetning:	HKD56.60M
Bruttogevinst:	HKD25.99M (45.92 %)
EPS:	HKD-0.130

FY	2023
Omsetning:	HKD56.60M
Bruttogevinst:	HKD25.99M (45.92 %)
EPS:	HKD-0.130

FY	2022
Omsetning:	HKD54.09M
Bruttogevinst:	HKD-24.69M (-45.65 %)
EPS:	HKD-0.340

FY	2021
Omsetning:	HKD76.88M
Bruttogevinst:	HKD39.17M (50.96 %)
EPS:	HKD-0.191

Financial Reports:

No articles found.

Ascletis Pharma Inc

Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China and internationally. The company offers Ritonavir oral tablet, a pharmacokinetic booster of various oral antiviral drugs targeting viral proteases and a component of the approved oral antiviral drug Paxlovid; ASCLEVIR and GANOVO for the treatment of Hepatitis C virus. It is also developing ASC22 for treating chronic hepatitis B (CHB) and human immunodeficiency virus functional cure; ASC42 for chronic hepatitis B functional cure; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, ASC42, ASC43F FDC, ASC44F FDC, and ASC45F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma, drug resistant breast cancer, and KRAS mutant non-small cell lung cancer; ASC61 and ASC63 for advanced solid tumors; ASC60 to treat solid tumors; and ASC40 for the treatment of acne, Ascletis Pharma Inc. was founded in 2013 and is headquartered in Hangzhou, the People's Republic of China.